Ceftazidime-Avibactam Susceptibility Breakpoints Against Enterobacteriaceae and Pseudomonas aeruginosa
| Autor: | Todd Riccobene, Shampa Das, Gregory G. Stone, Wright W. Nichols, Paul Newell, Katrina Yates, Angela Wardman, Helen Broadhurst, Merran MacPherson, Ian A. Critchley |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
030106 microbiology Microbial Sensitivity Tests Clinical Therapeutics medicine.disease_cause Ceftazidime Microbiology 03 medical and health sciences 0302 clinical medicine Pharmacokinetics Enterobacteriaceae Drug Resistance Multiple Bacterial medicine Humans Pharmacology (medical) 030212 general & internal medicine Pharmacology Clinical Trials as Topic biology Pseudomonas aeruginosa business.industry Liter biology.organism_classification Ceftazidime/avibactam Anti-Bacterial Agents Clinical trial Regimen Drug Combinations Infectious Diseases Pharmacodynamics business Azabicyclo Compounds medicine.drug |
| Zdroj: | Antimicrobial Agents and Chemotherapy |
| Popis: | Clinical susceptibility breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa for the ceftazidime-avibactam dosage regimen of 2,000/500 mg every 8 h (q8h) by 2-h intravenous infusion (adjusted for renal function) have been established by the FDA, CLSI, and EUCAST as susceptible (MIC, ≤8 mg/liter) and resistant (MIC, >8 mg/liter). The key supportive data from pharmacokinetic/pharmacodynamic analyses, in vitro surveillance, including molecular understanding of relevant resistance mechanisms, and efficacy in regulatory clinical trials are collated and analyzed here. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|